Levothyroxine
Regulatory milestones approvals, filings & regulatory actions · 10 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | LEVOLET | — | 2021-12-17 – 2022-08-05 | fda.gov ↗ |
| Label expansions (3) | US (FDA) | THYRO-TABS | — | 2016-05-19 – 2022-04-14 | fda.gov ↗ |
| Label expansion | US (FDA) | EUTHYROX | — | 2018-09-14 | fda.gov ↗ |
| Label expansions (2) | US (FDA) | LEVO-T | — | 2004-06-23 – 2011-03-09 | fda.gov ↗ |
| Label expansion | US (FDA) | UNITHROID | — | 2004-12-13 | fda.gov ↗ |
| Approved | US (FDA) | UNITHROID | — | 2000-08-21 | fda.gov ↗ |
Trials 91 · started per year
Also used as a comparator or background therapy in 53 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT06373523 Background | Sep 2024 → Jun 2025 overdue | NAFLD1, fibrotic liver disease | Post Graduate Institute of Medical Education and Research, Chandigarh | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT03106935 Comparator | Jul 2015 → Dec 2017 | pregnancy loss, recurrent, 4 | Second Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT04868045 Background | Apr 2021 → Feb 2023 | thyroid cancer | Memorial Sloan Kettering Cancer Center | Withdrawn | No outcome recorded |
| Phase 1 | NCT01557504 Background | Jul 2012 → Apr 2014 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00535561 Comparator | Jun → Sep 2007 | hypothyroidism, iron deficiency anemia | Duzce University | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT04178928 Comparator | Jan 2020 → Jan 2021 | hypothyroidism | Ain Shams University | Unknown | No outcome recorded |
| Phase 1/2 | NCT03098433 Comparator | Oct 2017 → Jun 2019 | — | Virginia Commonwealth University | Completed | No outcome recorded |
| Phase 1/2 | NCT00238030 Comparator | Dec 2004 → May 2009 | — | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed | No outcome recorded |
| Phase 210 trials | ||||||
| Phase 2 | NCT07424183 Background | Jun 2026 → Jun 2027 expected | hypothyroidism | University of Pennsylvania | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05526144 Comparator | Apr 2023 → Dec 2029 expected | fibrotic liver disease, metabolic dysfunction-associated steatohepatitis | VA Office of Research and Development | Recruiting | No outcome recorded |
| Phase 2 | NCT05712421 Comparator | Feb 2023 → May 2025 | hypothyroidism | Neuvosyn Laboratories, LLC | Completed | No outcome recorded |
| Phase 2 | NCT05412979 Comparator | Apr 2022 → Oct 2023 | hypothyroidism | Sention Therapeutics, LLC | Completed | No outcome recorded |
| Phase 2 | NCT05804149 Background | Aug 2020 → Sep 2022 | menstrual disorder | Cairo University | Completed | No outcome recorded |
| Phase 2 | NCT04124705 Comparator | Oct 2019 → Jun 2021 | hypothyroidism | Allergan | Completed | No outcome recorded |
| Phase 2 | NCT03627611 Comparator | Aug 2018 → Jun 2020 | hypothyroidism | Oslo University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT03289403 Comparator | Mar 2018 → Sep 2023 | autoimmune thyroid disease, infertility disorder | Aljazeera Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01391962 Background | Jul 2011 → Nov 2023 | alveolar soft part sarcoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00106119 Comparator | Mar 2005 → Nov 2013 | thyroid gland disorder | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 39 trials | ||||||
| Phase 3 | NCT06660823 Comparator | Nov 2024 → Jun 2025 | euthyroid sick syndrome | Ain Shams University | Completed | No outcome recorded |
| Phase 3 | NCT06276205 Background | Mar 2024 → Jan 2025 | hyperlipidemia, hypothyroidism, lip disorder | King Edward Medical University | Completed | No outcome recorded |
| Phase 3 | NCT05894954 Background | Jul 2023 → Oct 2025 | cognitive impairment with or without cerebellar ataxia, dementia | Alzheimer's Prevention and Reversal Project, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT06036576 Comparator | Mar 2022 → May 2023 | pregnancy loss, recurrent, 4, thyroid gland disorder | Al-Kindy College of Medicine | Completed | No outcome recorded |
| Phase 3 | NCT03390530 Comparator | Jan 2022 → Dec 2025 | intracerebral hemorrhage | Albert Einstein College of Medicine | Withdrawn | No outcome recorded |
| Phase 3 | NCT03898622 Comparator | Oct 2018 → Jan 2019 | chronic kidney disease, hypothyroidism | Hospital Civil de Guadalajara | Completed | No outcome recorded |
| Phase 3 | NCT03391154 Comparator | May 2017 → Aug 2020 | thyroid hormone metabolism, abnormal | Ain Shams University | Completed | No outcome recorded |
| Phase 3 | NCT01486667 Comparator | Oct 2011 → Oct 2013 | hyperlipidemia | King Saud University | Unknown | No outcome recorded |
| Phase 3 | NCT01436994 Comparator | Jul 2004 → Dec 2014 | thyroid gland disorder | Newcastle-upon-Tyne Hospitals NHS Trust | Completed | No outcome recorded |
| Phase 411 trials | ||||||
| Phase 4 | NCT06653907 Comparator | Oct 2024 → Dec 2026 expected | pregnancy disorder with abortive outcome, thyroid gland disorder | Yang Zhang | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05247476 Comparator | Oct 2021 → Mar 2022 | postsurgical hypothyroidism, thyroid gland papillary carcinoma | Zhongshan Hospital Xiamen University | Unknown | No outcome recorded |
| Phase 4 | NCT04288115 Comparator | Mar 2021 → Oct 2022 | hypothyroidism | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 4 | NCT06641440 Background | Jan 2018 → Dec 2023 | pregnancy loss, recurrent, 4 | Centre for Endocrinology and Reproductive Medicine, Italy | Completed | No outcome recorded |
| Phase 4 | NCT02211053 Comparator | Jul 2014 → Dec 2016 | — | Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal | Terminated | No outcome recorded |
| Phase 4 | NCT01660126 Comparator | May 2014 → Nov 2016 | hypothyroidism | NHS Greater Glasgow and Clyde | Completed | No outcome recorded |
| Phase 4 | NCT01848171 Comparator | Jul 2013 → Jul 2023 | hypothyroidism | Shandong Provincial Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01831869 Comparator | Apr 2013 → Apr 2022 | hypothyroidism | Shandong Provincial Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT05371262 Comparator | May 2011 → May 2018 | congenital hypothyroidism | Federico II University | Completed | No outcome recorded |
| Phase 4 | NCT01276782 Comparator | Jan → Jun 2011 | systemic lupus erythematosus | Johns Hopkins University | Withdrawn | No outcome recorded |
| Phase 4 | NCT00206375 Background | May 2003 → Sep 2011 | hypothyroidism | Baylor College of Medicine | Terminated | No outcome recorded |
| Phase not applicable15 trials | ||||||
| — | NCT07568574 Background | Mar 2026 → May 2028 expected | — | Enhanced Emirates Limited | Enrolling by invitation | No outcome recorded |
| — | NCT06652113 Background | Nov 2024 → Mar 2035 expected | autoimmune thyroid disease, habitual spontaneous abortion | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| — | NCT06353555 Comparator | Oct 2023 → Jun 2025 | euthyroid sick syndrome, intracerebral hemorrhage | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| — | NCT04600349 Comparator | Feb → Dec 2020 | Hashimoto thyroiditis | University of Bucharest | Completed | No outcome recorded |
| — | NCT04472988 Background | Jan → Dec 2020 | Hashimoto thyroiditis | University of Bucharest | Completed | No outcome recorded |
| — | NCT03024151 Comparator | Dec 2016 → Nov 2017 | anxiety, depressive disorder, thyroid cancer | Inje University | Completed | No outcome recorded |
| — | NCT02317926 Comparator | May 2015 → May 2018 | hypothyroidism | Walter Reed National Military Medical Center | Unknown | No outcome recorded |
| — | NCT03095963 Comparator | Jan 2014 → Oct 2016 | hypothyroidism | Azienda USL Modena | Completed | No outcome recorded |
| — | NCT01832753 Comparator | Jan 2013 → Oct 2017 | Down syndrome, hypothyroidism | Children's Hospital of Philadelphia | Completed | No outcome recorded |
| — | NCT01739972 Comparator | May 2012 → May 2014 | peripheral hypothyroidism | Walter Reed National Military Medical Center | Unknown | No outcome recorded |
| — | NCT02509858 Comparator | Feb 2009 → Feb 2014 | diabetes mellitus | Attikon Hospital | Completed | No outcome recorded |
| — | NCT00565890 Comparator | Dec 2005 → Mar 2011 | thyroid gland disorder | Tokyo Women's Medical University | Completed | No outcome recorded |
| — | NCT00230802 Comparator | Jul 2005 → Jul 2010 | hypothyroidism, pregnancy disorder | Brigham and Women's Hospital | Completed | No outcome recorded |
| — | NCT00846755 Comparator | Mar 2005 → Mar 2008 | pregnancy disorder, thyroid gland disorder | Ospedale V. Fazzi | Completed | No outcome recorded |
| — | NCT00715572 Comparator | Mar 2002 → Feb 2004 | hypothyroidism | I.M. Sechenov First Moscow State Medical University | Completed | No outcome recorded |
Evidence & citations 59 cited values
Every value below carries the sentence it was read from. 150 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | levothyroxine | “Concomitant use of thyroid hormone (eg, levothyroxine) is permitted during the study provided the participant has been receiving a stable dose for at least 12 weeks prior to...” NCT01557504 ↗96“Prospective, Single Dose, Randomized, Open Label, Comparative, Cross-study to Establish Bioequivalence Between the New Formulation and the Approved Formulation for...” NCT03979274 ↗ “Atrophic subtype support may include: estradiol, progesterone, testosterone, DHEA, pregnenolone, levothyroxine, liothyronine, hydrocortisone.” NCT05894954 ↗ “the study aim to detect the effect of low dose levothyroxine 50 ug on pregnant females and compare it with others receiving placebo” NCT03391154 ↗ “The participants randomised in this group will continue taking the classical treatment prescribed for Hashimoto (Levothyroxine)” NCT04600349 ↗ “The participants randomised in this group will continue taking the classical treatment prescribed for Hashimoto (Levothyroxine)” NCT04472988 ↗ “while on a continuous block-replacement regimen (+BRT, n = 48, median dose 15 mg methimazole and 100 μg levothyroxine)” PMID 21175612 ↗ Dec 2010 “The relationship between probiotics and levothyroxine (LT4) requirement has not yet been investigated.” PMID 29184537 ↗ Nov 2017 “The intervention will start with Levothyroxine 50 mcg daily with regular blinded dosis titration.” NCT04354896 ↗ “despite adequate levels of TSH after starting levothyroxine (LT4) therapy” PMID 35572853 ↗ May 2022 “75 micrograms of levothyroxine only daily for three months” NCT06641440 ↗ “levothyroxine treatment group (50 µg/day)” NCT06999278 ↗ “Euthyrox (levothyroxine)” NCT01379170 ↗ |
| Known as | Eferox | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Eltroxin | “The patients were treated with levothyroxine (Eltroxin, Glaxo) at a starting dose of 50 mcg per day.” NCT00498238 ↗ |
| Known as | Eltroxin (Levothyroxin, GlaxoSmithKline Pharma) | “Eltroxin (Levothyroxin, GlaxoSmithKline Pharma)” NCT00770016 ↗ |
| Known as | eltroxin 50 | “will receive 50 ug of levothyroxine (eltroxin 50) aspen,Egypt throughout the pregnancy” NCT03391154 ↗ |
| Known as | Ermeza | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Euthyrox | “Levothyroxine sodium tablets (Euthyrox, 50 μg) will be given 12.5μg \~50 μg daily based on patients' TSH levels and weights as described above.” NCT06652113 ↗3“Maintain the original antipsychotic regimen combined with levothyroxine sodium tablets (Euthyrox), 50 μg/day for 8 weeks.” NCT07011953 ↗ |
| Known as | Euthyrox/levothyroxine | “Euthyrox/levothyroxine” NCT01379170 ↗ |
| Known as | Eutirox | “Prospective, Single Dose, Randomized, Open Label, Comparative, Cross-study to Establish Bioequivalence Between the New Formulation and the Approved Formulation for...” NCT03979274 ↗ |
| Known as | Evotrox | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | L-Thyroxine | “Patients were randomly assigned to one of four treatments: placebo, folinic acid (FA), L-thyroxine, or FA+L-thyroxine, administered for 12 months.” PMID 31281181 ↗ Jul 201910“patients who received an increased dose of L-thyroxine, 25 mcg, n = 50” NCT06135948 ↗ |
| Known as | L-Thyroxine Christiaens | “Levothyroxine (L-Thyroxine Christiaens®) is used in the treatment of hypothyroidism.” NCT01916304 ↗ |
| Known as | L-thyroxine henning | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Levaxin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Levo-t | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Levolet | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Levothroid | “Levothroid® Tablets 300 μg” NCT00648700 ↗ |
| Known as | Levothyrox | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | levothyroxin | “Drug: levothyroxin” NCT03391154 ↗ |
| Known as | Levothyroxine sodique | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Levothyroxine Sodium | “Levothyroxine sodium tablets (Euthyrox, 50 μg) will be given 12.5μg \~50 μg daily based on patients' TSH levels and weights as described above.” NCT06652113 ↗17“Maintain the original antipsychotic regimen combined with levothyroxine sodium tablets (Euthyrox), 50 μg/day for 8 weeks.” NCT07011953 ↗ “Levothyroxine sodium new formulation” NCT01916304 ↗ “Levothyroxine Sodium Tablets 300 μg” NCT00648700 ↗ “Levothyroxine Sodium (LT4) Tablets” NCT06653907 ↗ “Levothyroxine Sodium (LT4) Tablets” NCT07424183 ↗ “Drug: Levothyroxine Sodium” NCT03977207 ↗ “Drug: Levothyroxine Sodium” NCT03281083 ↗ “Drug: Levothyroxine Sodium” NCT03191188 ↗ “Drug: levothyroxine sodium” NCT00921050 ↗ “Drug: Levothyroxine Sodium” NCT05228184 ↗ |
| Known as | Levothyroxine sodium anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Levothyroxine sodium hydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Levothyroxine sodium pentahydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Levothyroxine Sodium Tablets | “Drug: Levothyroxine Sodium Tablets” NCT04953195 ↗ |
| Known as | Levothyroxinum natricum anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Levotiroxina de sodio | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Levoxyl | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Liotrix (t4) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | LT4 | “Patients will be randomized to levothyroxine or placebo (similar in size, shape, and color to levothyroxine) via permuted blocks stratified by two TSH levels (\>3.0-5.0 and...” NCT03977207 ↗22“A recent trial showed that 1:3 μg:μg liothyronine (L-T3) substitution for levothyroxine (L-T4) achieving near-identical TSH levels resulted in a significant decrease in weight...” PMID 23585666 ↗ Apr 2013 “We report a randomized, multicenter, open-label trial (ClinicalTrials.gov: NCT03096613) to investigate the clinical benefits of levothyroxine (L-T4) administration in...” PMID 38537636 ↗ Mar 2024 “administration of levothyroxine (LT4) to TPO-Ab-positive euthyroid pregnant women with a prior history of loss may be considered given its potential benefits in comparison with...” NCT06652113 ↗ “The effect of levothyroxine (LT4) therapy for subclinical hypothyroidism (SHypo) on appendicular bone geometry and volumetric density has so far not been studied.” PMID 35381390 ↗ Apr 2022 “To evaluate the effect of levothyroxine (LT4) replacement therapy on nonalcoholic fatty liver disease (NAFLD) in subclinical hypothyroidism (SCH) patients.” PMID 28473851 ↗ Apr 2017 “Treatment with proton pump inhibitors (PPIs) and antacids affects the gastrointestinal absorption of levothyroxine sodium (LT4) tablets.” PMID 37885233 ↗ Nov 2023 “Objective: To determine whether low dose levothyroxine (LT4) therapy may be a potential treatment for diabetic patients with NAFLD.” NCT03281083 ↗ “Levothyroxine (LT4) is widely used for hypothyroidism; evaluating its adjuvant role in obesity management is clinically relevant.” NCT07332273 ↗ “The intervention group will receive oral levothyroxine (L-T4) initiated on postnatal day 14 at a starting dose of 8 ug/kg/day.” NCT07625722 ↗ “Levothyroxine sodium (LT4) is an effective drug prescribed as replacement therapy for patients with hypothyroidism” NCT01189344 ↗ “The relationship between probiotics and levothyroxine (LT4) requirement has not yet been investigated.” PMID 29184537 ↗ Nov 2017 “two 6-month dosing strategies of levothyroxine (LT4) in patients aged 65 years and older” NCT06073665 ↗ “Combining DTE with levothyroxine (L-T4) may overcome current therapeutic bottlenecks.” NCT07239674 ↗ “Levothyroxine (LT4) and placebo (a look-alike inactive substance, a "sugar pill")” NCT04782856 ↗ “despite adequate levels of TSH after starting levothyroxine (LT4) therapy” PMID 35572853 ↗ May 2022 “active comparator group of oral Levothyroxine (L-T4) during pregnancy” NCT06653907 ↗ “L-thyroxine (L-T4) is the intervention for each arm/group.” NCT00565864 ↗ “Liquid stable levothyroxine (L-T4) Tirosint-SOL” NCT04747275 ↗ “Levothyroxine Sodium (LT4) Tablets” NCT07424183 ↗ “levothyroxine (LT4) in patients” NCT06999278 ↗ |
| Known as | Monosodium l-thyroxine hydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Novothyrox | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | NSC-259940 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | NSC-36397 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Oroxine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Reference Euthyrox | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05174000 ↗ |
| Known as | SK&F 1-6528 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Sodium levothyroxine pentahydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Soloxine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Synthetic levothyroxine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Synthroid | “Levothyroxine Oral Tablet [Synthroid]” NCT06790589 ↗5“Brand Name Levothyroxine (Synthroid)” NCT00403390 ↗ “Growth hormone + Synthroid + Lupron” NCT00206375 ↗ “Abbott's Synthroid® 200 μg tablets” NCT00648557 ↗ |
| Known as | T4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02103998 ↗ |
| Known as | T4 (liotrix) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Test Euthyrox | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05174000 ↗ |
| Known as | Thyquidity | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Thyro-tabs | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | thyroxine | “Thyroxine (T4) administration is advocated in the management of organ donors; however, the bioavailability of oral thyroxine is unknown in this patient population.” PMID 23884915 ↗ Jul 201312“Thyroxine is then added in a low replacement dose as the thyroid hormone levels fall into the lower half of the laboratory normal range.” NCT01436994 ↗ “Patients will receive treatment with intra-venous thyroxine 100mcg once on admission and additional 100mcg after 12 hours.” NCT02086799 ↗ |
| Known as | Thyroxine sodium | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Thyroxine sodium salt | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Thyroxine, i-125 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Thyroxine, i-131 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Thyroxine, l- | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Tirosint | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Known as | Tirosint-SOL | “Tirosint®-SOL (levothyroxine sodium) oral solution (IBSA Pharma Inc.)” NCT05228184 ↗1“Liquid stable levothyroxine (L-T4) Tirosint-SOL” NCT04747275 ↗ |
| Known as | Unithroid | ChEMBL registry synonym — accepted as the source's own label CHEMBL1624 ↗ |
| Action | Restore | “thyroid hormone replacement” NCT00388297 ↗ |
| Modality | Other / unclassified | “thyroid hormone replacement” NCT04354896 ↗ |
| Route | Intravenous | “Patients were randomized to receive either an oral or intravenous dose of T4 (2 μg·kg⁻¹).” PMID 23884915 ↗ Jul 2013 |
| Route | Oral | “Patients were randomized to receive either an oral or intravenous dose of T4 (2 μg·kg⁻¹).” PMID 23884915 ↗ Jul 2013 |